Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.
AI Summary
Key Findings
Abstract
OBJECTIVES: We investigated whether atorvastatin might decrease insulin sensitivity and increase ambient glycemia in hypercholesterolemic patients. BACKGROUND: Clinical trials suggest that some statin treatments might increase the incidence of diabetes despite reductions in low-density lipoprotein (LDL) cholesterol and improvement in endothelial dysfunction. METHODS: A randomized, single-blind, placebo-controlled parallel study was conducted in 44 patients taking placebo and in 42, 44, 43, and 40 patients given daily atorvastatin 10, 20, 40, and 80 mg, respectively, during a 2-month treatment period. RESULTS: Atorvastatin 10, 20, 40, and 80 mg significantly reduced LDL cholesterol (39%, 47%, 52%, and 56%, respectively) and apolipoprotein B levels (33%, 37%, 42%, and 46%, respectively) after 2 months of therapy when compared with either baseline (all p
Affiliation
Department of Cardiology, Gachon University, Gil Medical Center, Incheon, Korea. [email protected]
External References
- PubMed ID:
- 20298928
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.